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ABSTRACT
Objective: To describe changes in immune
parameters observed during long-term methotrexate
(MTX) therapy in patients with active rheumatoid
arthritis (RA) and explore correlations with
simultaneously measured MTX pharmacokinetic (PKC)
parameters.
Design: Prospective, open-label, long-term
mechanism of action study.
Setting: University clinic.
Methods: MTX was initiated at a single weekly oral
dose of 7.5 mg and dose adjusted for efficacy and
toxicity for the duration of the study. Standard
measures of disease activity were performed at
baseline and every 6–36 months. Serum cytokine
measurements in blood together with lymphocyte
surface immunophenotypes and stimulated peripheral
blood mononuclear cell (PBMC) cytokine production
were assessed at each clinical evaluation.
Results: Cytokine concentrations exhibited multiple
significant correlations with disease activity measures
over time. The strongest correlations observed were for
interleukin (IL)-6 (r=0.45, p<0.0001 for swollen joints
and r=0.32, p=0.002 for tender joints) and IL-8 (r=0.25,
p=0.01 for swollen joints). Significant decreases from
baseline were observed in serum IL-1B, IL-6 and IL-8
concentrations. The most significant changes were
observed for IL-6 (p<0.001). Significant increases from
baseline were observed in IL-2 release from PBMCs ex
vivo (p<0.01). In parallel, multiple statistically
significant correlations were observed between MTX
PKC measures and immune parameters. The change in
swollen joint count correlated inversely with the change
in area under the curve (AUC) for MTX (r=−0.63,
p=0.007).
Conclusions: MTX therapy of patients with RA is
accompanied by a variety of changes in serum cytokine
expression, which in turn correlate strongly with clinical
disease activity and MTX pharmacokinetics (PKCs).
These data strongly support the notion that MTX
mediates profound and functionally relevant effects on
the immunological hierarchy in the RA lesion.
INTRODUCTION
Rheumatoid arthritis (RA) affects ∼0.5–1%
of the world’s population with an estimated
prevalence of up to 2 million cases in the
USA alone.1 In numerous clinical guidelines,
methotrexate (MTX) is the anchor treatment
for RA management.2–8 Patients exhibit
dose-dependent clinical improvements while
on MTX.9 Toxicity is a more common reason
to discontinue therapy than is lack of effi-
cacy.6 10 Recent guidelines of the American
College of Rheumatology have reinforced
the central role of MTX in the treatment
of RA.11
Key messages
What is already known about this subject?
There are no studies of the mechanism of action of
methotrexate (MTX) which include serial prospect-
ive measures of serum cytokines and simultaneous
measures of pharmacokinetics and clinical vari-
ables. This study was carried out over a 3-year
period.
What does this study add?
The study shows for the first time that MTX treat-
ment is associated with significant decreases in
serum interleukin (IL)-6 and IL-8 and that these
decreases correlate well with both long-term,
sequential measures of MTX PK and with clinical
outcomes.
How might this impact on clinical practice?
The recognition that MTX has a significant effect on
serum IL-6 will provide insight into its MOA.
Perhaps more importantly, it explains the further
changes in transaminase levels and possible addi-
tive effects on IL-6 when used with these biological
response modifiers and Janus kinase inhibitors.
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In spite of a proliferation of reports of the effect of
MTX on various in vitro, ex vivo or animal models of
inflammation, its mechanism of action in patients with
RA remains incompletely understood.12 Few investiga-
tions have examined directly the potential effects of
MTX on biochemical, immune or inflammatory para-
meters in vivo or ex vivo in high-intensity, near-patient
immune functional assays. Nor has the relationship
between MTX pharmacokinetics (PKCs) and immune
functional parameters been examined formally or in
detail. In particular, although the PKCs of MTX in RA
are well described,13–17 we are unaware of prior attempts
to seek correlations between PKC measures in patients
with RA on MTX and simultaneously assessed immune
markers of disease activity.
We report here prospective measurements of immune
and PKC parameters in a cohort of patients with active
RA beginning treatment with MTX and remaining on
therapy over a period of 3 years. We describe MTX-
associated changes in serum cytokines and lymphocyte
phenotypic markers which correlate with the measure-
ments of disease activity as well as with drug PKCs. We
provide for the first time convincing PKC evidence sup-
porting the immune modulatory role of MTX in RA
over long treatment intervals.
METHODS
Patients: Seventeen patients with definite RA18 were
recruited from the outpatient population of the Division
of Rheumatology at Albany Medical College and con-
secutively enrolled. Patients had active disease as previ-
ously defined2 and signed informed consent. Patients
were approached consecutively and no patient who was
asked to participate refused. Patients had never before
received MTX and discontinued their prior slow-acting
antirheumatic drug at least 1 month prior to begin-
ning MTX therapy. Patients continued non-steroidal
anti-inflammatory drugs or prednisone <10 mg daily
throughout the study according to prior prescription. The
prednisone dose was held constant for 1 month prior to
study entry and no intra-articular steroid dose was allowed
1 month prior to initiation of the study. MTX was initiated
at a dose of 7.5 mg weekly and increased incrementally to
achieve maximal clinical efficacy and decreased for tox-
icity as previously described in a different cohort.2 All
patients were followed by the same clinical investigator
( JMK) throughout the study. Patient demographic and
clinical characteristics are shown in table 1.
Clinical evaluations: Clinical evaluations were per-
formed at baseline and every 6 months thereafter
through 36 months. Clinical evaluations recorded at
each visit consisted of the number of tender and swollen
joints (66 diarthrodial joints examined), the duration of
morning stiffness in minutes, the interval from time awa-
kening to the first onset of fatigue in minutes, grip
strength, and patient and physician evaluation of pain
and global arthritis activity using a five-point scale were
0=absent, 1=mild, 2=moderate, 3=severe and 4=very
severe. Adverse events were recorded at the time of each
clinical evaluation after questioning the patient regard-
ing possible toxic reactions to MTX.
Laboratory: Laboratory values determined at each visit
consisted of a complete blood count, platelet count,
Westergren erythrocyte sedimentation rate, rheumatoid
factor (nephelometry) and serum chemistry including
serum aspartate aminotransferase γ-glutamyl transferase,
alkaline phosphatase, albumin, total bilirubin, total
protein and creatinine. The absolute number of neutro-
phils and lymphocytes were calculated at each visit by
multiplying the total white cell count (WCC) by the
percentage of these cells reported on the differential
count.
Immune studies: In order to establish whether sampling
for immune parameters would be acutely affected by
weekly MTX dosing, blood samples for cytokines and
lymphocyte phenotypic analyses were obtained on two
occasions at the time of each study evaluation. The first
sample was obtained at 8:00 of the day of the clinical evalu-
ation and initiation of PKC blood sampling but prior to
the weekly MTX dose given to the patient that day (pre).
The second sample was obtained 24 hours after the first,
following the weekly MTX dose (post). Sera were ali-
quoted and frozen at −70°C and all longitudinal samples
of each individual later were thawed and quantified by
ELISA for the following cytokines: interleukin (IL)-1B
(T-cell Diagnostics, Cambridge, Massachusetts, USA); IL-2
and IL-6 (Biosource, Camarillo, California, USA); IL-4 and
IL-8 (R&D Systems, Minneapolis, Minnesota, USA). All
ELISAs were performed in accordance with the appropri-
ate manufacturer’s protocol. In addition, peripheral blood
mononuclear cells (PBMCs) were obtained by
Ficoll-Hypaque (Pharmacia) from the patients at the same
time points. These cells (1×106 cells/mL/well; 24-well
plate) were stimulated with concanavalin A (5 mg/mL)
and supernatants were collected after 24 hours and frozen
for later analysis of IL-1B, IL-2 and IL-4 as described above.
Table 1 Clinical and demographic features of patients
with rheumatoid arthritis prior to MTX therapy (N=17)
Age (years) (mean, SD) 60.9 (12.1)
Sex (F:M) 10:7
RA disease duration (months) 133 (130)
NSAIDs (%) 17 (100)
Prior DMARDs (n) 0=3
1=8
2=5
3=1
Haemoglobin (g/dL) (mean, SD) 12.6 (2.0)
Western ESR (mm/hour) (mean, SD) 67.9 (34.1)
RF (%) 14 (82)
Prednisone (N) (mean dose (SD)) 10 (5.4 (2.4))
DMARDs, disease-modifying anti-rheumatic drugs; ESR,
erythrocyte sedimentation rate; F, female; M, male; MTX,
methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor;
NSAIDs, non-steroidal anti-inflammatory drugs.
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Flow cytometric analysis: Blood was collected by veni-
puncture into EDTA blood collection tubes and the
immunophenotyping of the PBMC by flow cytometry
was performed by the whole blood lysis method as previ-
ously described.19 The flow cytometry was performed
with a Becton Dickson FACScan and analysed with Lysys
II or Paint-A-GatePlus software. The lymphocytes within
the PBMC preparation were gated by forward angle and
side light scatter. The purity of the lymphocyte gate and
assessment of lymphocytes not within this gate is deter-
mined with antibodies to CD14 and CD45. The specific
monoclonal antibodies employed for lymphocyte subset
analyses were used in the following combinations: CD4/
CD8/CD3 (T-cell subsets); CD4/CD29 (memory helper
T cells); CD4/CD45RA (naïve helper T cells); CD5/
CD10 (B1 and B2 cells). Lymphocyte immunopheno-
type counts were calculated by multiplying the percent-
age of the subpopulation obtained by FACS by the total
absolute lymphocyte count obtained by coulter counter
analysis and laboratory differential cell count. Both
samples were obtained at the same blood draw.
Pharmacokinetics: PKCs of MTX were measured at each
study visit when clinical, laboratory and immune para-
meters were also obtained. Patients received MTX at 8:00
after an overnight fast. Blood samples were collected
prior to the 8:00 dose and at the 0.5, 1, 2, 3, 4, 6, 8 and
24 hours after the dose. Urine was collected for 24 hours
for MTX and creatinine analysis. Serum and urine cre-
atinine concentrations were determined by the clinical
laboratory. Blood and urine were analysed by fluores-
cence polarization immunoassay (FPIA) for MTX con-
centration. Areas under the serum concentration versus
time curve (AUC) were calculated by the trapezoidal rule
through 8 hours. Area under the curve from 8 to
24 hours was determined using the log-trapezoidal rule
or Simpson’s approximation. The area under the curve
from the last measured concentration to infinity (AUC24
oo) was determined by dividing the final concentration by
the terminal elimination rate constant. AUC from time 0
to infinity (AUCo 24) was the sum of the AUC0 24 oo plus
AUC24 oo. The terminal elimination rate constant was
determined using the non-linear curve-fitting program
RSTRIP. Renal clearance was determined by dividing the
urine MTX by the AUC0 24. Creatinine clearance was
determined using standard formula. Systemic clearance
(clearance/F, where F=oral bioavailability) was deter-
mined as dose divided by AUCO oo. As the dose of MTX
was adjusted to clinical response throughout the investi-
gation, the PKC studies were conducted with different
MTX doses throughout the study.
Statistics: Kolmogorov-Amirnoff tests were conducted to
determine whether the data for key variables follows
Gaussian (normal) distributions. None of these tests were
statistically significant (α=0.05), which indicated that the
data were not significantly non-Gaussian. The sample sizes
in most of the analyses were large enough to eliminate con-
cerns about using parametric statistical tests. A number of
one-sample t-tests were performed on the data to
determine whether average changes from baseline or
average changes from previous visits were statistically sig-
nificant for different clinical, laboratory and PKC variables.
A Bonferroni correction was applied to all of the values.
The initial correlation analyses were a series of pair-
wise Pearson correlations to examine the extent to
which variables in the data were correlated with one
another. Variables involving changes from baseline or
changes from previous visits were correlated with each
other; variables involving direct measurements were
independently correlated with each other.
A series of stepwise multiple linear regression models
were performed. In these analyses, the dependent
variables were the changes in clinical measurements
between visits while the independent variables were the
change in PKC variables between visits. Stepwise regres-
sion was used to limit the final models to only those
independent variables that added significantly to the
explanatory power of the models.
Chronological setting of investigation: The study was
planned and completed at the Albany Medical College
in the late 1990s and has never before been published
in any form in any journal. Thus, access to biological
agents was not available. Similarly, outcome measures
such as a Disease Activity Scale in 28 joints (DAS28)
were not in vogue and C reactive protein (CRP) mea-
sures were not performed.
RESULTS
Clinical results
As expected, significant improvements in multiple clinical
and laboratory parameters were observed on MTX therapy
(table 2).
Laboratory
Haemoglobin increased from baseline and achieved sig-
nificance at p<0.001 after 18 months of MTX therapy
(table 2). Other laboratory changes from baseline are
also seen in table 2.
Cytokines
The timing of sampling around MTX ingestion was of
particular concern. Therefore, differences between sam-
ples obtained immediately prior to and 24 hours
following a sequential MTX dose (pre and post) from
baseline through month 36 were calculated for each
immune parameter. Only serum IL-6 levels decreased
significantly between the presamplings and postsam-
plings across all study counts (20.1 (21.5) to 14.2 (15.2),
p=0.0003 after correction); none of the other differ-
ences observed for immune moieties between prevalues
and postvalues approached statistical significance
(p>0.20). We therefore used only the prevalues (ie,
those obtained just prior to the weekly MTX dose (see
the Methods section)).
Changes from baseline values of the serum cytokines
and lymphocyte subsets in patients receiving MTX are
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Table 2 Mean (SD) change with time in clinical and laboratory values in patients with RA treated with MTX (n=17)
Months in study
Baseline (SD) Values 6 7 8 12 18 24 30 36
Tender joints 19.2 (8.9) −10** (9) −11 −13** −15+ −10* −9* −6 −14**
(8) (12) (10) (10) (13) (12) (12)
Swollen joints 18.6 (8.2) −8+ −9+ −11+ −12+ −9* −11+ −9+ −11+
(7) (7) (7) (7) (10) (6) (7) (6)
AM stiffness (in minutes) 283.3 (365.8) −223* −198 −336* −148* −169 −181 −128 −187
(350) (429) (343) (231) (338) (343) (232) (444)
Hrs to fatigue 6.3 (2.5) 3.1 3.7 2.6 2.3 4.0 0.2 −0.4 –
(5.1) (5.0) (4.0) (–) (–) (1.7) (2.3)
Pt. pain (0–5) 2.4 (0.62) −0.5 −0.8** −0.8* −0.9* −0.9* −0.9** −0.8** −0.6
(0.9) (1.0) (1.0) (0.95) (1.0) (0.9) (0.8) (1.0)
Pt. global (0–5) 2.4 (0.62) −0.7* −0.9+ −0.8+ −1.1+ −0.8* −0.8** −0.7** −0.6
(0.9) (0.8) (0.7) (0.9) (0.9) (0.9) (0.8) (1.2)
Haemoglobin, g/dL 12.6 (2.0) 0.7* 0.1 0.8* 0.8* 1.3+ 0.6 0.9** 0.7
(1.0) (1.3) (1.0) (1.2) (0.6) (1.6) (1.0) (1.6)
Platelets 103/mm3 390.3 (130.5) −57** −65** −73+ −64** −71** −71* −106+ −100*
(57) (70) (56) (75) (40) (106) (90) (106)
AST (IU) 18.2 (6.3) 4.8 5.0 5.5 10.0* 2.9 −2.0 1.7 −0.5
(14.6) (20.2) (18.7) (14.5) (14.0) (8.3) (13.0) (8.7)
ESR, mm/hour 68 (32) −35.5+ −34.9+ −35.0+ −31.9** −11.3 −32.9** −32.5+ −41.8**
(23.1) (29.8) (20.9) (27.5) (78.0) (35.4) (30.8) (35.0)
WCC, 103/mm3 9.0 (2.5) −1.9+ −1.8** −1.7+ −1.1 −1.9* −1.2 −3.2+ −2.7+
(1.5) (1.8) (1.3) (2.3) (1.9) (2.1) (2.9) (1.6)
RF (nephelometry) 420.9 (598.6) −19.3 −116.3 −148.0 −265.7 −119.8 −230.8 −49.3 −384.1
(174.5) (410.3) (354.5) (570.9) (867.7) (691.7) (803.8) (732.8)
Weekly MTX Dose (mg) 7.5 (0.0) 13.1 13.8 13.3 13.6 13.8 14.5 15.6 15.5
*p<0.05.
**p<0.01.
+p<0.001.
AST, aspartate aminotransferase; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; WCC, white cell count.
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seen in table 3. Significant changes over time were
observed in the levels of IL-6, IL-8 and IL-1B. Each
measurement of serum IL-6 through 30 months of treat-
ment was significantly decreased from baseline. Serum
IL-1B and IL-8 levels also consistently decreased after
MTX treatment. Serum IL-2 and IL-4 levels did not sig-
nificantly change after MTX treatment; however, the ex
vivo ability of MTX to modify IL-2 production was
observed in that Con A-stimulation of lymphocytes from
the MTX-treated patients did produce significantly
higher levels of IL-2 at 7, 12, 18, 24, 30 and 36 months.
Lymphocyte populations
We observed few changes in cell populations. Only the
CD4/CD29 at week 30 reduced in a statistically signifi-
cant manner (p=0.013; table 3).
Correlation of clinical and laboratory values with cytokines
Consistently significant correlations were observed
between serial measurements of IL-6 in sera and multiple
simultaneously assessed clinical parameters (table 4). As
would be expected if IL-6 was related to disease activity,
serum IL-6 levels strongly correlated with swollen joints
(r=0.45, p<0.0001), physician global assessment of disease
activity (r=0.47, p<0.0001), patient global assessment of
disease (r=0.32, p=0.001), tender joints (r=0.32, p=0.002),
patient evaluation of pain (r=0.29, p=0.003) and morning
stiffness (r=0.27, p=0.007). In addition, an inverse correl-
ation was observed between IL-6 and the interval to the
first onset of fatigue (r=−0.31, p=0.043). Positive correla-
tions were also observed between IL-8 in the sera and
multiple measures of disease activity including tender
and swollen joints and both physician and patient
Table 3 Mean (SD) change from baseline in cytokine values, and absolute lymphocyte counts with time in patients with RA
treated with methotrexate (n=17)
Months in study
Cytokine (pg/mL) Baseline 6 7 8 12 18 24 30 36
IL-1BPt 188.2 (173.2) 130 −94 12 92 15 102 160 225
(353) (165) (134) (174) (13) (102) (98) (178)
IL-1BSH 72.2 (94.2) −34+ −41** −29** −19 −39* −26* −32 −72
(51) (50) (33) (48) (33) (40) (49) (94)
IL-2P 300.0 (197.5) 183 330* 193 503** 285* 540* 289** 398*
(314) (424) (352) (442) (268) (572) (232) (388)
IL-2S 55.3 (11.4) 32 12 16 7 22 12 −9 −31
(23) (23) (32) (60) (32) (6) (65) (35)
IL-4P 26.7 (36.9) −9 −4 10 9* 11 21 6 17
(23) (51) (35) (9) (5) (21) (7) (10)
IL-4S 6.2 (8.2) −4 −4 −12 2 −5 −7 −0.4 –
(14) (11) (12) (3) (11) (12) (2)
IL-6S 44.1 (25.3) −33+ −28** −28* −25** −37** −37+ −46+ −2.8
(21) (27) (35) (27) (25) (26) (25) (32)
IL-8S 457.4 (722.1) −424* −302 −419 −481 −826* −411* −344 −111
(663) (736) (669) (881) (760) (642) (627) (487)
Baseline 6 7 8 12 24 30 36
CD4 645 (519) 310 149 −35 −25 −136 144 –
(446) (798) (443) (493) (581) (687)
CD8 282 (182) −23 12 −10 −69 18 −26 –
(140) (137) (186) (186) (156) (109)
CD4/CD8 255 (485) −183 −75 69 −203 −26 −274 –
(335) (187) (135) (795) (81) (410)
CD4/CD29 426 (288) −16 23 −6.3 −170 −16 −194++ –
(111) (214) (187) (322) (261) (102)
CD4/CD45RA 531 (315) −44 −207 84 58 −58 −110 –
(255) (352) (319) (221) (395) (253)
CD5/CD19 99 (173) −10 – −110 982 −7.5 −73 –
(42) (114) (–) (13) (114)
t supernatants from peripheral blood mononuclear cells.
H S=serum.
*p<0.05.
**p<0.01.
***Values obtained by multiplying total absolute lymphocyte counts by the percentage of each subpopulation as measured by FACS analysis
(see the Methods section).
+p<0.001.
++p<0.05.
IL, interleukin; RA, rheumatoid arthritis.
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Table 4 Pearson correlations of clinical, laboratory and lymphocyte subset values with cytokines in patients with rheumatoid
arthritis on MTX therapy
Tender
joints
Swollen
joints
AM
stiffness
Patient global
assessment
Physician
global
assessment
Patient
evaluation
of pain
Interval
to
fatigue
Adverse
events*
IL1-B serum –† – – – – – – r=0.38
p=0.002
IL1-B
supernatants
– – – – – – – –
IL-2 serum
(N=105)
– – – – – r=−0.19
p=0.05
–
IL-2
supernatants
p=−0.24
p=0.02
– – – r=−0.27
p=0.014
– – –
IL-4 serum – – – – – – – –
IL-4
supernatants
(N=105)
– – – – r=−0.32
p=0.00
r=−0.31
p=0.00
r=−0.67
p=0.034
–
IL-6 serum
(N=68)
r=0.32
p=0.002
r=0.45
p<0.0001
r=0.27
p=0.007
r=0.32
p=0.001
r=−0.47
p<0.0001
r= 0.29
p=0.003
r=−0.31
p=0.043
–
IL-8 serum
(N=67)
r=0.24
p=0.020
r=0.25
p=0.013
r=0.25
p=0.023
r=0.26
p=0.010
r=0.25
p=0.015
r=0.24
p=0.021
– –
WCC Neutrophils Lymphocytes Rheumatoid factor titer ESR Haemoglobin
IL-1B (N=105) serum – – – – r=23
p=0.021
–
IL-1B (N=105) supernatants – – – – – –
IL-2 (N=105) serum – – – r=35
p=0.05
– –
IL-2 (N=105) supernatants r=0.24
p=0.013
r=−0.22
p=0.05
r=0.22
p=−0.05
– – –
IL-4 (N=105) serum r=0.30
p=0.002
– r=0.44
p=0.016
– – –
IL-4 (N=84) supernatants – – r=0.33
p=0.005
– – –
IL-6 (N=103) serum r=0.37
p<0.0001
r=0.37
p<0.0001
r=0.24
p=0.023
r=0.21
p=0.05
– –
IL-8 (N=92) serum r=0.33
p=0.001
r=0.34
p=0.001
– – – –
Tender
joints
Swollen
joints
AM
stiffness
Patient global
assessment
Physician global
assessment
Patient
evaluation of
pain
Interval to
fatigue
CD4 (n=53) – – – – – – –
CD8 (n=53) r=0.27
p=0.05
– – – r=0.30
p=0.03
– –
CD4/CD8
(n=53)
r=0.36
p=0.008
– r=0.27
p=0.05
r=0.31
p=0.02
– –
CD4/CD29
(n=53)
r=0.27
p=0.05
– – – r=0.36
p=0.009
r=0.26
p=0.059
r=0.26
p=0.058
CD4/CD45
RA (n=53)
– – – – – – –
CD5/CD19
(n-28)
– – – – – – –
*Indicates the total number of investigator-related episodes of toxicity reported at the time of a clinical evaluation which were judged to be
related to MTX.
†Indicates a non-significant correlation.
ESR, erythrocyte sedimentation rate; IL, interleukin; MTX, methotrexate; RA, rheumatoid arthritis; WCC, white cell count.
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assessment of global arthritis activity. The correlations
with IL-8 were somewhat weaker than those seen with
IL-6."
We observed an inverse correlation between IL-2 in
the sera and patient evaluation of pain (r=−0.19,
p=0.05). Most of the correlations of both serum and
supernatant IL-2 and IL-4 and disease activity were
inverse, consistent with their expression reflecting some
restoration of immune homeostasis.
Other correlations between serum cytokines and
laboratory values are seen in table 4.
Correlations of clinical and laboratory values with
lymphocyte phenotypic markers
Both tender joint count and physician global assessment
of disease activity correlated with CD8 (r=0.27, p=0.05
and r=0.30, p=0.03, respectively), CD4/CD8 (r=0.36,
p=0.008 and r=0.31, p=0.02, respectively) and CD4/CD29
(r=0.27, p=0.05 and r=0.36, p=0.009, respectively) counts
(table 4). CD4/CD8 cell numbers also correlated with
patient global assessment of disease activity (r=0.27,
p=0.05). No correlations were observed between CD4
cells and clinical disease activity. As expected, positive cor-
relations were observed between absolute lymphocyte
counts at each visit and lymphocyte phenotypic markers
(table 5).
An inverse correlation was observed between CD4/
CD45 and rheumatoid factor (RF) (r=−0.67, p=0.007),
while a trend towards a positive correlation was seen
between RF and CD4/CD29 (r=0.50, p=0.056) and CD4/
CD8 (r=0.42, p=0.002). CD4/CD8 cells also exhibited a
correlation with platelet count (r=0.33, p=0.016).
Interestingly, both CD4/CD29 and CD4/CD45 RA cells
correlated with total WCC (r=0.39, p=0.005 and r=0.28,
p=0.05).
Correlation of mMTX PKCs with clinical, immune and
laboratory parameters
Correlations between repeat MTX PKC measurements
and clinical, immune and laboratory parameters are
seen in table 6. A significant inverse correlation was
observed between the change in AUC between the visits
and the number of swollen joints (r=−0.63, p=0.007).
A regression analysis using change in tender joints
between visits as a dependent variable and the change
between visits in all PKC variables revealed an inverse
correlation with the change in AUC (r=0.42, r2=18,
p=0.0005). A regression analysis using change in swollen
joints between visits showed an inverse correlation with
change in the AUC (r=0.30, r2=0.9, p=0.015).
Mean weekly MTX dose correlated directly with IL-2
concentrations in sera (r=0.20, p=0.038) and inversely
with IL-6 in sera (r=−0.30, p=0.016), platelet count (r=
−0.17, p=0.017 and CD8 cells (r=−0.48, p=0.009)).
Direct correlations of AUC were observed only for IL-2
in supernatants from stimulated PBMCs (r=0.23,
p=0.045) while an inverse correlation was observed with
CD8 cells (r=−0.41, p=0.028).
Correlation of cytokines with each other
Cross correlations of prospectively and simultaneously
measured cytokines can be seen in online supplementary
table S7.
DISCUSSION
We have demonstrated significant changes in the con-
centrations of several cytokines in sera and arising from
ex vivo PBMC stimulation along with changes in lympho-
cyte phenotypic markers from a population of consecu-
tive patients with active RA beginning therapy with
MTX. By obtaining serial measures of these immune
parameters along with simultaneous assessments of clin-
ical and laboratory function over a period of 36 months
of treatment, we have been able to derive correlations
between these immune measures and simultaneously
assessed MTX PKCs. We were less interested in compos-
ite efficacy outcomes such as the American College of
Rheumatology (ACR)composite disease activity score or
disease activity score (DAS), and more interested in indi-
vidual clinical measures and their reaction to both PKCs
Table 5 Pearson correlations of lymphocyte subsets with laboratory values in patients with rheumatoid arthritis on
methotrexate
WCC Neutrophils Lymphocytes Rheumatoid factor Platelet count ESR
CD4 (n=52) – – r=0.82
p=0.001
– –
CD8 (n=52) – r=0.66
p=0.01
r=0.79
p=0.001
– –
CD4/CD8 (n=52) – – – r=0.33
p=0.016
–
CD4/CD29 (n=52) r=0.39
p=0.005
– – r=0.50
p=0.056
– –
CD4/CD45 (n=52) r=0.28
p=0.05
– r=0.73
p=0.005
r=−0.67
p=0.007
– –
CD5/CD19 (n=28) – – – – – –
ESR, erythrocyte sedimentation rate; WCC, white cell count.
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of MTX and the multiple cytokines and lymphocyte
immunophenotypes reported. In this way, we could dis-
tinguish the associations of both MTX PKCs and the
immune parameters with the individual, and disparate,
clinical measures reported. We believe that this
approach is preferable to associations with composite
measures for deriving meaningful clinical insights. To
our knowledge, this is the first investigation to combine
prospective sequential measures of clinical outcomes
along with MTX PKC and immune measures of disease
activity over periods which are significantly longer than
any randomised controlled trial.
We report highly significant decreases in serum IL-1B,
IL-6 and IL-8 on start of MTX. These changes were per-
sistent over 36 months. The highly significant decreases
in IL-6 and IL-8 correlated strongly with the changes in
multiple targeted and specific measures of disease activity
including both swollen and tender joints as well as patient
and physician assessment of global disease activity. Given
the known systemic biological impact of IL-6 especially, it
is likely that these findings may account for at least some
of the beneficial effects of MTX in patients with RA.
Decreases from baseline measures in IL-6 and other
cytokines have been reported in patients with RA on
gold therapy,20 hydroxychloroquine21 and corticoster-
oids22 as well as MTX.23 24 Barrerra et al23 reported
serial measurement of serum IL-6 along with tumour
necrosis factor (TNF)-α and sIL-2R over a period of
48 weeks in a combined cohort of patients with RA on
azathioprine and MTX. Correlations were sought with
clinical outcomes and some were found although
decreases in sIL-2R ‘were associated with clinical
improvements’. Crilly et al24 reported significant
decreases in IL-6 after 12 weeks of MTX, which were not
seen at 24 weeks, perhaps because the mean weekly
MTX dose in that study was only 6.5 mg/week. The
functions of IL-6 have been extensively reviewed25–28
and include the stimulation of hepatocyte synthesis of
acute phase reactants, B-cell differentiation27 and stimu-
lation of osteoclastogenesis.28 IL-6 may also be involved
in the cartilage degradation seen in RA,29 30 and is pro-
tective for hepatocyte injury.31 Thus our data have
important functional implications.
The consistent and highly significant decreases of IL-6
that we observed with MTX treatment are striking. IL-6
correlations with disease activity and both total WCC
and absolute neutrophil counts were stronger than for
those of the other measured cytokines, suggesting a
central role in disease pathogenesis, perhaps manifest at
least in regulating bone marrow function and circulatory
properties of the measured leucocyte subsets. Recent
studies identifying a STAT3 transcriptional profile in
CD4T cells in early RA are consistent with these observa-
tions.32 IL-6 may be derived from several cellular sources
including T cells and monocytes. The significant positive
correlations between serum levels of IL-6 and both IL-8
and IL-1B and the lack of significant effects of MTX on
T-cell-derived cytokines IL-2 and IL-4 in sera suggest a
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common MTX effect on monocytes/macrophage-
derived cytokines.
In spite of the significant and consistent decreases in
serum IL-1B from baseline values seen with our patients
with RA receiving MTX, no correlations of IL-1B with clin-
ical markers of disease were observed (table 4), suggesting
that at least the clinical outcomes we measured are not
tightly linked to the presence of circulating IL-1. However,
IL-1B in serum was the only cytokine that correlated with
patients reporting adverse events to MTX (table 4). The
significance of this observation is presently unclear.
Memory T cells may be important in early RA synovitis33
although parallel, not incompatible models for pannus
formation have been proposed.34 Early RA synovial biop-
sies are enriched for clonal selection consistent with local
antigen-driven T-cell expansion.34 While most investiga-
tions of the effect of MTX on circulating blood lympho-
cytes have reported no consistent effect,35 36 alterations in
CD8 cells in blood from patients with RA on MTX have
been reported.37 38 Patients with recent onset RA have an
increase in CD8+ lymphocytes in blood and synovial
fluid.38 Both peripheral blood and synovial fluid from
patients with RA exhibited a decrease in CD8+/CD45RA+
suppressor effector cells and normal percentages of CD4
+/CD29+ helper inducer or memory cells.39 Notably CD8
cells recirculate from lymph nodes to the circulation and
as such may be a population whose circulatory frequency
is such as to allow them to report on such functional
changes after initiation of MTX therapy. Whether this
confers functional primacy is unclear at this stage.
We observed no significant changes from baseline in
lymphocyte subsets with the exception of a decrease in
the CD4+/CD29+ population after 30 months of MTX.
We did, however, observe several correlations with serial
measurements of lymphocyte surface phenotypes with
both clinical and laboratory parameters of disease activity
(tables 4 and 5). It is of interest that cells with the CD4
immunophenotype exhibited no correlations with
disease activity while circulating blood CD8, CD4/CD8
and CD4/CD29 helper inducer or memory cells exhib-
ited correlations with several parameters of disease
including tender joints. The majority of lymphocytes in
the synovial fluid of patients with RA are known to be of
the CD4/CD29 immunophenotype,39 and we observed
some correlations between circulating cells of this lineage
and markers of disease activity (tables 4 and 5). It is
possible that MTX has a greater effect on these memory
helper T cells in synovium than the generally
non-significant decreases which we observed in blood
(table 4). It should be noted that in our hands, the CD4/
CD8 phenotype is the result of a serum factor influence
that occurs in about 45% of the patients with RA tested
and the <2% of the ‘healthy’ controls.40 This phenom-
enon has been suggested to be due to an artifactual stain-
ing from serum immunoglobulin.41 Whether the CD4/
CD8 double-positive phenotype results from immunoglo-
bin or some other serum factor, the level of this con-
founding factor must be modified by MTX. The absence
of more significant correlations of lymphoid subset
changes with disease status may be due to the specific
marker analysis employed or restriction of analysis to per-
ipheral blood. Numerous lymphocyte subsets exist in dif-
ferent states of maturation and activation. Since a minor
lymphoid population could be responsible for disease
maintenance, a general screen with a limited number of
markers could miss the population of importance.
Changes in synovial T-cell populations may also not paral-
lel those observed in blood.
We also performed detailed and repeated MTX PKC
measurements and examined correlations with laboratory
and immune parameters (table 6). We believe that this
is the first time that MTX PKC measures have been
repeated over these very long treatment intervals with
simultaneous measures of disease activity, as well as clin-
ical, cytokine, lymphocyte immunophenotype and labora-
tory measures. We found that production of IL-2 from
PBMC supernatants obtained at the time of the PK mea-
sures correlated with the AUC for MTX, while weekly
MTX dose correlated with serum levels of IL-2. The
increases from baseline in IL-2 from serum in stimulated
PBMCs during MTX treatment were observed at multiple
time points (table 3) but did not correlate with most mea-
sures of disease activity (table 4). IL-2 deficiency in serum
and synovial fluid of patients with RA has been noted for
some time.42 43 It is possible that the mechanism of the
MTX-induced increase in IL-2 reflects MTX-induced
alterations in polyamine production.44 45 Expansion of
IL-2-dependent Treg subsets is an intriguing hypothesis
that arises and deserves further consideration as this
might account for robust durable response over time as
homeostatic regulatory responses are recovered in patients
on MTX. Emerging Treg populations have been reported
also for TNFi, for example, etanercept, adalimumab.46
All other correlations between MTX PKCs and
immune parameters were inverse as would be expected
if increasing the weekly dose resulted in a decrease in
the value being measured. Inverse correlations were
observed between AUC and CD8 cells and MTX Cmax
and CD8 and CD4/CD8 lymphocytes as well as total
WCC and platelet counts. We observed variable increases
in the production of IL-2 and inconsistent effects on the
number of CD4 and CD8 cells. The alterations in
lymphocyte phenotypic markers were generally not sig-
nificant when compared with baseline values but the dir-
ection of change in response to MTX is evident by the
clinical correlations observed (tables 4 and 5).
In summary, we have described significant alterations
in prospectively measured serum and PBMC-derived
cytokines, as well as lymphocyte phenotypic markers,
from blood in patients with RA on MTX along with sim-
ultaneously measured clinical and PKC parameters. We
have performed these measures prospectively, at regular
6-month intervals, over a period of 36 months. We have
demonstrated for the first time that an increase in the
MTX AUC per se produces significant decreases in
swollen and tender joint counts. We believe that the
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scope, duration and breadth of the measurements are
unique. While the studies were actually performed just
prior to the biological era, we believe that the results
actually have become increasingly compelling.
Owing to the unique and notable design of the study
in sequential patients starting MTX, we could derive cor-
relations between all of these measures and individual
clinical parameters of disease. The weaknesses include
the fact that we could of course have included many
other measures of immune function and that a total of
only 17 patients were included. We however believe that
it is unlikely that the measures we report are skewed
from what would be expected in other patients starting
MTX, but we acknowledge that our observations should
be replicated. It should also be noted that most mea-
sures of PK and immune function have typically
included smaller numbers in the range which we report.
In addition, the serum cytokine measured may not be
reflective of those in synovium, or the totality of the
implicate immune response in RA. Nevertheless, serum
measures of cytokines are typically reported in associ-
ation with IL-6 and Janus kinase ( JAK) inhibitors and
are an accepted surrogate for the mechanism of action
of these agents.47 It is possible that the alterations in
cytokine production and lymphocyte immunopheno-
types may be secondary events, which occur when
disease improves. We do not therefore easily infer causal-
ity in our analyses and their interpretation. A control
group was simply not feasible over the time course of
this trial. However, the compelling relationship between
the immune changes reported and simultaneous PK
measures strongly suggest that the findings are related to
MTX intervention and are not simply a surrogate for
general disease improvement. The significant decreases
in serum IL-6 observed with MTX may explain further
increases in transaminase enzymes when the drug is
combined with either IL-6, or JAK, inhibitors.48 49 While
a single prior publications of the effects of MTX on
lymphocyte immunophenotypes50 has been previously
published, it was of only 16 weeks duration and did not
have the benefit of simultaneous measurements of PK
measures. We believe that in an era of expanded atten-
tion to biomarkers of disease, our findings, which correl-
ate with PK parameters and disease activity over 3 years,
should help illuminate the field.
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